WALNUT CREEK, Calif., Aug. 1, 2018 /PRNewswire/ -- Paradigm Outcomes, the market leader in managing catastrophic and
"Integrating these solutions into Paradigm's enterprise offering expands the scope and impact of our care management solutions, enabling us to reach more people and improve more lives," said John Watts, CEO, Paradigm Outcomes. "These solutions advance our ongoing efforts to build a new standard for the next generation of outcomes-focused care management."
The expanded clinical services deepen Paradigm's expertise across the care continuum and extend access to a network of experts to better serve catastrophic cases, complex medical issues on long term cases, pain, and early and effective back injury treatment.
The new group will operate as a wholly owned subsidiary of Paradigm and maintain the product and service brand names. Paradigm will begin offering these new solutions immediately and will provide uninterrupted service to existing customers.
About Paradigm Outcomes
Paradigm Outcomes is the market leader in managing catastrophic and complex cases for the workers' compensation industry. Paradigm's core business provides clinically-driven comprehensive care management programs for people with acquired brain injuries, spinal cord injuries, multiple traumas, amputations, burns and chronic pain, achieving 5x better medical outcomes and lowering total costs by 40% compared to industry benchmarks. Together with its wholly owned subsidiaries The ALARIS Group, Encore Unlimited and ForeSight Medical, Paradigm works to improve health outcomes and lower medical spend for high-cost, complex cases.
View original content:http://www.prnewswire.com/news-releases/paradigm-outcomes-expands-catastrophic-and-complex-care-solutions-300690047.html
SOURCE Paradigm Outcomes
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All